Lucira Health, Inc. develops disposable Point-of-Care molecular tests for rapid and accurate diagnosis of infectious disease. By eliminating centralized instrument-based testing, Lucira Health's products will empower physicians to be nimbler and more informed with on-the-spot diagnostic information. The platform will also enable consumers to take the first step in their healthcare management through at-home diagnosis and a companion mobile app to provide follow up treatment.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/05/19 | $15,000,000 | Series B |
Data Collective Eclipse Ventures Seraph Group  ShangBay Capital Sunstone Management Y Combinator | undisclosed |
